USA flag logo/image

An Official Website of the United States Government

Search


Narrow Search Filters:
Agency:HHS
Year:20122011
Download to spreadsheetPrint
Displaying 2376 – 2397 of 2397 Awards
Company: ARTA BIOSCIENCE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: The androgen receptor (AR) remains a key therapeutic target for prostate cancer (PCa), even in castration resistant PCa (CRPC). Current therapies target AR by blocking androgen synthesis or competitive antagonism. ARTA Bioscience is developing an early lead, ABS-001, a non-competitive AR inhibitor… more
Company: ROCKLAND, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: The RON and c-MET signal pathways are critical regulators of cell growth, survival, migration, differentiation, and drug resistance. High levels of activated RON or c-MET have been observed in a number of human cancers. Activation of RON and c-MET by phosphorylation initiates a signal transduction… more
Company: ROCKLAND, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: In response to this NCI solicitation, Rockland proposes to develop a novel method to assay the pharmacodynamic (PO) properties of anti-cancer small molecules targeting the PI3K/mTOR/AKT signaling pathway by quantitatively and independently measuring the phosphorylation of each unique AKT isoform in… more
Company: APOCELL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: Rare cell sublets in peripheral blood, such as circulating tumor cells (CTCs) has been used as biomarkers for cancer progression. In addition, growing evidence suggests that CTC isolation from a blood sample may allow reliable early detection and molecularcharacterization of cancer at diagnosis or… more
Company: AKROTOME IMAGING Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: Phase I - Topic 307 Breast cancer is the most common cancer in women. The major complication after breast conserving surgery (BCS) is local recurrence of the cancer. The key factor in reducing local recurrence is obtaining a: clean" margin of normal tissue around the removed lump. This is… more
Company: CELLSIGHT TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: Phase I - Topic 307 There is a critical need to predict the efficacy and potency of adoptive cellular immunotherapies (ACIT) as these therapies gain traction in treatment of cancer with over 90 clinical trials planned this year. A prominent approach in ACIT involves introducing activated T cells… more
Company: MILLISECOND SOFTWARE, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: The tests will be published to our company website where they can be run by anyone with a Windows PC and access to the web. Data from these test runs will be recorded and saved to a secure location Millisecond web server. The source code for the scripts will be made available for download.
Company: ALLELE BIOTECHNOLOGYANDPHARMACEUTICALS INC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: The main objective of this contract is to generate VHH antibodies against 10 addiction-relevant proteins. Protocols will be established for efficiently identifying single chain VHH antibodies from llamas. Both synthetic peptides and recombinant proteinswill be used to immunize llamas.
Company: ANTAGEN PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: AWith a long-term objective to efficiently manufacture protein therapeutics, the Contractor developed a mammalian expression vector pATG that incorporates human DNA regulatory elements to render long-term cell line stability, ensures the most stringent selection of high producers, and uses the… more
Company: EXACT SPORT LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: Under this SBIR Phase I contract, the Contractor responds to Research Topic 127, "Improving Measures of Addiction Risk." The Contractor shall develop a practical instrument for detecting youths at elevated risk for substance use disorder (SUD). Phase I will focus on development of a… more
Company: EIGER GROUP INTERNATIONAL, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs… more
Company: MOLECULAR SENSING, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Molecular interactions form the basis of healthy metabolism as well as the manifestation of disease, and comprise the very foundation of drug treatment. Tools available to study molecular interactions in their nascent environment and physiological concentrations… more
Company: PRESAGE BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific… more
Company: ANTIOP, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): There is a significant unmet medical need to provide additional pharmacologic treatments for treatment and prevention of opioid overdose. This Fast Track STTR project proposes to apply drug delivery technologies to develop a novel use for a nasally delivered… more
Company: VIRTUAL PHANTOMS, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): This project aims to develop a commercial software product, VirtualDoseTM, for calculating and analyzing patient radiation doses from x-ray computed tomography (CT) examinations. Despite its essential role in radiology, CT is responsible for raising the… more
Company: MICRO VIDE, LLC Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only… more
Company: GLIKNIK INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: Background Information Rituxan and Herceptin are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158… more
Company: PICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: Under this SBIR Phase II project, the Contractor shall develop and evaluate their " Clinical Trial Participant Management System." This product will be comprehensive, integrated IVR phone and Web (email and text) delivered database system designed to facilitate the management of clinical… more
Company: GENOME EXPLORATIONS INC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: Alcohol abuse and its related health effects are estimated to have an economic cost in the US that approaches $200 Billion per year. However, current tests for alcohol use/abuse are not reliable except when administered within several hours of intoxication. Moreover, current clinical tests for… more
Company: OPEN SOURCE MEDICAL SOFTWARE CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: Develop a repository of human cardiovascular and cardiopulmonary computer models consisting of realistic, image-based anatomic models of large arteries and airways, generic, distal vascular beds, and representative blood and tissue properties. Simulationsbased on repository data will have… more
Company: SID TECHNOLOGIES LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: SID Technologies is developing intradermal devices aiding healthcare workers in performing intradermal injections. The goal is to provide an alternative, easier to learn method of intradermal drug delivery to the Mantoux technique, in order to expand the population of healthcare workers who may… more
Company: Applied Decision Science, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: There is a need for better decision support tools to help doctors quickly assess patients' cancer screening status. Colorectal cancer screening is especially difficult to track because there are many screening options that take place over time and in different settings. The proposed research will… more
Displaying 2376 – 2397 of 2397 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.